Pharmaceuticals, Biotechnology and Life Sciences
Piramal Pharma Solutions (PPS), has invested $10 million for a new wing at the Riverview site dedicated to the production of high potency active pharmaceutical ingredients (HPAPIs) with low Occupational Exposure Levels (OELs).
Edesa Biotech may continue with its clinical investigation of potential treatment for chronic allergic contact dermatitis EB01, a novel sPLA2 inhibitor, after FDA’s approval.
MONTGOMERY, Ala.–(BUSINESS WIRE)–Remove the three paragraphs with headings INDICATIONS AND USAGE, PRIMARY HYPERLIPIDEMIA AND MIXED DYSLIPIDEMIA, and LIMITATIONS OF USE…
$10M investment as Series B extension, bringing total amount raised to $35M –
– Direct investment for the discovery of gut targeted, small molecule therapeutics in oncology utilizing Axial’s novel platform technology
AUSTIN, Texas–(BUSINESS WIRE)–Elligo Health Research, a healthcare-enabling research organization, welcomes Brandon Cormier, Jody Casey, and Faith Holmes, MD, FAAFP, AAHPM,…
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered…
The combination did not demonstrate statistical significance in outperforming the single agents in the overall population
HENDERSON, Nev.–(BUSINESS WIRE)–Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today the…
-$MRK #MRK–At a meeting with the investment community today, Merck (NYSE: MRK), known as MSD outside the United States and Canada, will outline how its science-led strategy and broad pipeline of promising transformative therapies and vaccines will position the company to deliver strong growth and shareholder value over the long term.
PureTech will continue to leverage leadership in Brain-Immune-Gut axis biology to develop novel categories of therapeutics